Metanoia Press · In preparation · Synthetic
The family's exception, and why it belongs in the picture
MDMA is the outlier of the classic set. It is not really a "psychedelic" in the same sense: it doesn't primarily mimic serotonin at the 5-HT2A receptor the way the others do, and its signature is emotional warmth and openness rather than visions. Its trials in people with PTSD, a clinical population, brought it to an FDA decision in August 2024, and that decision has taught the whole field hard lessons about evidence and expectation. Our forthcoming book covers it for completeness, with the same attention to limits as to results. The PTSD trials are in a clinical population and do not describe healthy adults.
What the Book Will Cover
A different molecule, a different lesson
How it works
Why MDMA is an "empathogen," releasing serotonin rather than mimicking it, a genuinely different mechanism from the tryptamines.
The therapy story
Its place in the PTSD research that brought psychedelic therapy into the mainstream conversation.
The container
The setting and the therapeutic frame, and the open question of how much of any benefit they account for.
The limits
Neurotoxicity questions, the regulatory setbacks, and what the field learned from them.
The science in brief
MDMA works mainly by causing a large release of serotonin (along with dopamine and norepinephrine), rather than by directly activating the 5-HT2A receptor the way psilocybin and LSD do, which is why it produces closeness, trust, and reduced fear rather than classic visionary effects. That emotional profile is why it was studied in trauma-focused therapy research, in people with PTSD.
Its story is also a lesson in humility. The regulatory path for MDMA-assisted therapy has had significant setbacks, prompting hard questions about trial design, expectation effects, and how much of the benefit comes from the therapy versus the molecule. We treat that plainly: real unresolved questions, and a reminder that enthusiasm is not evidence.
Reliability: mechanism is well established (strong). The large trials were in people with PTSD, and their results are disputed, with notable regulatory setbacks. Full sources will accompany the finished book.